ESR1 and triple-negative breast carcinoma: It should be noted, however, that we observed 20E activity also in triple-negative breast cancer (TNBC) cell lines that lack ER [41], arguing that the wide range of pharmacological activities of 20E in tissues of different origins cannot be determined by only these targets.